Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582898 | 0.81 | LTB4R (0.44) | — | |
| SCHEMBL2583060 | 0.80 | MCL1 (0.52) | XDH | |
| SCHEMBL2586464 | 0.78 | ALDH1A1 (0.47) | P2RY12 | |
| SCHEMBL2578647 | 0.77 | ADORA2A (0.43) | FFAR4P2RY12KMO | |
| SCHEMBL2587393 | 0.76 | ADORA2A (0.44) | FFAR4P2RY12KMO | |
| SCHEMBL2586242 | 0.76 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL2580556 | 0.76 | LMNA (0.58) | — | |
| SCHEMBL12478630 | 0.75 | CNR2 (0.61) | FFAR4XDHKMOKDM1ANR1H4 | |
| SCHEMBL20515876 | 0.73 | ALOX15 (0.61) | XDHKMO | |
| SCHEMBL30438176 | 0.73 | ALOX15 (0.61) | XDHKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | FFAR4 151/4885P2RY12 1/4885XDH 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.